Frontal dopamine D(2/3) receptor binding in drug-naive first-episode schizophrenic patients correlates with positive psychotic symptoms and gender.
BACKGROUND
The aim of the study was to examine extrastriatal dopamine D(2/3) receptor binding and psychopathology in schizophrenic patients, and to relate binding potential (BP) values to psychopathology.


METHODS
Twenty-five drug-naive schizophrenic patients and 20 healthy controls were examined with single-photon emission computerized tomography (SPECT) using the D(2/3)-receptor ligand [123I]epidepride.


RESULTS
In the hitherto largest study on extrastriatal D(2/3) receptors we detected a significant correlation between frontal D(2/3) BP values and positive schizophrenic symptoms in the larger group of male schizophrenic patients, higher frontal BP values in male (n = 17) compared to female (n = 8) patients, and - in accordance with this - significantly fewer positive schizophrenic symptoms in the female patients. No significant differences in BP values were observed between patients and controls; the patients, however, had significantly higher BP in the right compared to the left thalamus, whereas no significant hemispheric imbalances were observed in the healthy subjects.


CONCLUSIONS
The present data are the first to confirm a significant correlation between frontal D(2/3) receptor BP values and positive symptoms in male schizophrenic patients. They are in agreement with the hypothesis that frontal D(2/3) receptor activity is significant for positive psychotic symptoms. Additionally, the data support a thalamic hemispheric imbalance in schizophrenia.
Center for Neuropsychiatric Schizophrenia Research, University of Copenhagen, Department of Psychiatry E, Bispebjerg Hospital, Copenhagen, Denmark. birte.glenthoj@cnsr.dk
Birte Y
BY
Glenthoj
Torben
T
Mackeprang
Claus
C
Svarer
Hans
H
Rasmussen
Lars H
LH
Pinborg
Lars
L
Friberg
William
W
Baaré
Ralf
R
Hemmingsen
Charlotte
C
Videbaek
D000328:Adult; D001549:Benzamides / Q000493:pharmacokinetics; D001931:Brain Mapping; D010054:Brief Psychiatric Rating Scale / Q000706:statistics & numerical data; D016022:Case-Control Studies; D003287:Contrast Media / Q000493:pharmacokinetics; D005260:Female; D005625:Frontal Lobe / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism*; D006801:Humans; D007456:Iodine Isotopes / Q000493:pharmacokinetics; D008297:Male; D011759:Pyrrolidines / Q000493:pharmacokinetics; D017448:Receptors, Dopamine D2 / Q000378:metabolism*; D050637:Receptors, Dopamine D3 / Q000378:metabolism*; D012559:Schizophrenia / Q000000981:diagnostic imaging / Q000378:metabolism*; D012565:Schizophrenic Psychology; D012727:Sex Characteristics; D015899:Tomography, Emission-Computed, Single-Photon / Q000379:methods
D001549:Benzamides; D003287:Contrast Media; D007456:Iodine Isotopes; D011759:Pyrrolidines; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; C063525:epidepride